Oral Contraceptives

Slide 1 · Oral contraceptives

Pathology of hormonal contraceptive exposure

Hormonal formulations and mechanisms

Cancer associations, thrombotic risk, and cardiovascular effects

Hepatocellular adenoma as a drug-associated pathology entity

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish combined and progestin-only oral contraceptives and recognize formulation heterogeneity.

Interpret site-specific cancer associations without inferring a universal cancer effect.

Connect estrogen-associated hypercoagulability to deep vein thrombosis and pulmonary embolism.

Recognize the morphology and key molecular subtypes of hepatocellular adenoma.

Slide 3 · Why oral contraceptives appear in a pathology chapter

Therapeutic agents can produce clinically significant adverse reactions.

Oral contraceptives are highly prevalent exposures, making even uncommon complications relevant.

The key pathology questions concern cancer, thrombosis, vascular disease, and liver neoplasia.

Therapeutic exposure

Systemic tissue responses

Clinical disease

Conceptual framework

Slide 4 · Adverse drug reactions: Mechanistic perspective

Adverse drug reactions may reflect a drug’s pharmacologic action or an unintended systemic effect.

The affected organ and individual susceptibility influence clinical expression.

Hormonal contraceptives exemplify exposure-dependent risks rather than a single toxicity syndrome.

Slide 5 · Oral contraceptives are not one exposure

Formulation

Combination estrogen + progestin

Progestin-only option

Exposure dimensions

Hormone dose

Type of progestin

Delivery route

The term covers differing estrogen–progestin compositions and progestin-only preparations.

Hormone dose and formulation have changed over time.

Associations must be interpreted for the actual formulation studied.

Slide 6 · Combined hormonal preparations

A combined oral contraceptive includes an estrogen component plus a progestin.

The combination alters reproductive endocrine physiology to prevent pregnancy.

Cancer and thrombotic associations should not automatically be assigned to every formulation.

Estrogen component

Progestin component

Contraceptive effect

Components and outcome

Slide 7 · Progestin-only oral contraception

Combined

Estrogen component

Progestin component

Progestin-only

No estrogen component

Specific progestin formulation

Some oral formulations contain no estrogen component.

Norgestrel (Opill) as a U.S. Over-the-counter progestin-only oral product.

Evidence from combined preparations cannot simply be transferred to progestin-only tablets.

Slide 8 · Oral versus other hormonal delivery systems

Robbins also notes transdermal and implantable hormonal contraception.

Delivery routes differ in pharmacokinetic exposure; They should not be conflated with oral therapy.

The actual question is which formulation, dosage, and delivery system an outcome study assessed.

Drug formulation

Dose + delivery system

Clinical exposure

Interpretation chain

Slide 9 · Primary contraceptive actions

Contraceptive action to suppression of ovulation or prevention of implantation.

The underlying hormone manipulation is a systemic intervention, not merely a local reproductive-tract exposure.

Systemic actions help explain why nonreproductive organs appear in the adverse-effect profile.

Hormonal contraception

Ovulation / implantation effects

Prevention of pregnancy

Mechanism: Textbook description

Slide 10 · The ovarian component of contraception

Ovulation suppression removes a necessary step in natural conception.

A pharmacologic reproductive effect can coexist with adverse responses in other tissues.

Clinical safety therefore cannot be inferred solely from contraceptive effectiveness.

Hormone exposure

Ovulation inhibited

Pregnancy prevented

Simplified physiology

Slide 11 · Implantation-related action in the source

Robbins also identifies prevention of implantation as a contraceptive mechanism.

This broad statement is not a formulation-specific mechanistic ranking.

Avoid claiming the same predominant mode of action for all oral contraceptives.

Slide 12 · How newer formulations change interpretation

Currently prescribed products typically contain less estrogen than earlier products.

It associates lower estrogen exposure with fewer side effects.

Historical risk estimates need formulation and dose context.

Earlier formulations

Lower-estrogen formulations

Non-identical risk profiles

Historical comparison

Slide 13 · Dose-dependent interpretation

The same name “oral contraceptive” can refer to materially different estrogen exposures.

A relative risk from one formulation may not generalize to a different formulation.

Formulation stratification is central when interpreting older and newer epidemiologic studies.

Slide 14 · Time since contraceptive exposure matters

Endometrial and ovarian cancer protection may remain long after contraception is discontinued.

Hepatocellular adenoma is associated particularly with prolonged exposure.

Current use and remote prior use should not be treated as biologically identical histories.

Slide 15 · Epidemiology needs exposure specification

Specify combination versus progestin-only exposure where data permit.

Distinguish dose, duration, and route; Age and smoking status can also modify risk.

Treat observed associations separately from demonstrated causal mechanisms.

Who was exposed?

What was the regimen?

What outcome occurred?

Study appraisal

Slide 16 · Outcomes differ by organ system

Potential protection

Endometrium; Ovary

Potential association

Cervix in HPV infection; Hepatic adenoma

Vascular risk

Venous thromboembolism; Context-specific arterial risk

Potential cancer protection at some sites and potential increased risk at others.

Thromboembolism is mechanistically linked to a hormone-induced procoagulant state.

Hepatocellular adenoma is a specific, recognizable benign neoplasm associated with exposure.

Slide 17 · Breast carcinoma: Wording matters

Robbins: Oral contraception

“Prevailing view” of no increase

Formulation-dependent evidence

Separate intervention

Menopausal hormone therapy

Different population and regimens

The Robbins oral-contraceptive passage states that the prevailing view is no increase in breast-cancer risk.

This is a source-specific summary, not an independently updated meta-analysis.

Do not extrapolate this statement to menopausal hormone therapy, which is discussed separately.

Slide 18 · Endometrial cancer: Protective association

An association between oral-contraceptive use and lower endometrial cancer risk.

The protective effect may remain after treatment is stopped.

This is an epidemiologic disease-endpoint statement, not a claim that individual endometrial lesions regress.

Slide 19 · The long duration of endometrial protection

During use

After discontinuation

Protection may persist for decades

Protection is described as lasting for decades after cessation.

Past exposure may therefore matter even when a patient is no longer taking contraception.

A durable association should not be confused with proof of a single permanent molecular mechanism.

Slide 20 · Ovarian cancer: Protective association

Robbins also reports a protective association for ovarian cancers.

The favorable association is separate from contraceptive efficacy.

The text does not provide a magnitude stratified by tumor subtype or progestin formulation.

Slide 21 · Ovarian protection may outlast exposure

Hormonal exposure

Exposure ends

Long-lasting association

The reported protection can persist for decades after stopping use.

Risk histories should distinguish current use from ever-use and previous duration of use.

Do not assign a precise absolute risk reduction without an appropriate primary study.

Slide 22 · Cancer sites cannot be pooled conceptually

Breast

No increase: Prevailing textbook view

Endometrium

Protective association

Ovary

Protective association

Cervix

Possible increase in HPV-infected females

Breast, endometrium, ovary, and cervix show different site-specific associations.

“Cancer risk” is not a single biological endpoint.

Interpret each organ within its relevant etiologic context.

Slide 23 · Cervical carcinoma requires HPV context

The oral-contraceptive section describes possible increased cervical cancer risk in women infected with HPV.

HPV infection is the relevant cofactor named.

Do not describe oral contraceptives as sufficient to cause cervical cancer.

Slide 24 · High-risk HPV: The main cervical carcinogen

High-risk HPV infection is the dominant etiologic factor in cervical cancer.

Persistent infection increases the likelihood of precursor lesions and invasive carcinoma.

The contraceptive association must be interpreted in this causal setting.

High-risk HPV infection

Persistence + precursor lesion

Cervical carcinoma

Primary etiologic pathway

Slide 25 · HPV E6 and E7 establish biologic plausibility

HPV E6

Impaired p53 activity

Reduced damage checkpoint

HPV E7

Impaired RB activity

Increased cell-cycle entry

High-risk HPV E6 promotes degradation of p53; E7 disrupts RB-mediated cell-cycle control.

Loss of tumor-suppressor function favors cell-cycle progression and mutation accumulation.

The source does not establish that contraceptives directly activate E6 or E7.

Slide 26 · HPV infection versus invasive cervical cancer

HPV infection is common; Only a subset becomes persistent and progresses.

An exposure associated with cancer in HPV-infected women should not be treated as synonymous with causing HPV infection.

Precancer and invasive carcinoma are distinct pathologic endpoints.

HPV infection

Persistent / dysplastic lesions

Invasive carcinoma

Disease progression

Slide 27 · Cervical risk: What the source does not establish

The passage uses “may increase” rather than asserting an unqualified causal effect.

No absolute probability, dose threshold, or additional molecular pathway is provided.

Cervical screening and HPV-centered prevention remain conceptually distinct from contraception.

Slide 28 · Separating etiologic factor from risk modifier

Etiologic driver

High-risk HPV

E6/E7 tumor-suppressor disruption

Possible modifier

Hormonal contraceptive exposure

Association conditional on HPV

An etiologic agent participates directly in carcinogenesis: High-risk HPV.

A risk modifier changes the probability of an outcome in an exposed subgroup: Oral-contraceptive association in HPV-infected females.

The two should not be merged into a single causal label.

Slide 29 · Venous thromboembolism is a central adverse outcome

Oral contraception with venous thrombosis and pulmonary thromboembolism.

The proposed mechanism is a hormone-induced hypercoagulable state.

The risk is clinically important even with lower-estrogen preparations.

Slide 30 · Magnitude: Relative venous thrombotic risk

Users versus reference

2–4× relative risk

Most cited studies report a 2- to 4-fold relative increase in venous thrombosis and pulmonary thromboembolism.

This range includes lower-dose products defined in the source as less than 50 μg of estrogen.

A relative increase is not an absolute event rate.

Slide 31 · Hepatic coagulation-factor synthesis

The acquired hypercoagulable state to increased hepatic production of coagulation factors.

The thrombosis chapter also notes decreased anticoagulant synthesis as a potential contributor.

The resulting prothrombotic balance favors venous clot formation.

Hormonal exposure

Hepatic clotting-factor shift

Hypercoagulability → VTE

Procoagulant sequence

Slide 32 · Hypercoagulability in Virchow’s triad

Virchow’s triad comprises hypercoagulability, altered blood flow, and endothelial injury.

Oral contraceptive use primarily enters the framework through acquired hypercoagulability.

Other coincident risks can affect different arms of the triad.

Hypercoagulability

Stasis / flow

Endothelial injury

Virchow’s triad • Schematic

Slide 33 · Deep vein thrombosis: Likely source of emboli

Venous thrombi frequently develop in deep veins of the leg.

Portions may detach and traverse the venous circulation and right heart.

An embolus may obstruct pulmonary arterial branches.

Deep leg vein thrombus

Venous flow / right heart

Pulmonary arterial embolus

Embolic route

Slide 34 · Deep venous thrombosis: Pathologic substrate

Stasis favors venous thrombus formation; Hypercoagulability amplifies the tendency to clot.

A DVT can be symptomatic or clinically silent before embolization.

The contraceptive exposure is a risk factor, not a morphologically unique thrombus subtype.

Slide 35 · Pulmonary thromboembolism: Immediate consequences

Pulmonary arterial obstruction creates ventilated but nonperfused lung regions.

Major obstruction also increases pulmonary vascular resistance and can cause acute right heart strain.

Severity depends on thrombus burden and cardiopulmonary reserve.

Pulmonary artery occlusion

Perfusion deficit + resistance

Respiratory / hemodynamic compromise

Consequences of embolization

Slide 36 · Pulmonary emboli: Recognizable morphology

Large emboli may lodge in the main pulmonary arteries or at their bifurcation as a saddle embolus.

Peripheral occlusions may produce hemorrhage or hemorrhagic infarction.

Classical pulmonary infarcts are peripheral wedge-shaped lesions.

Peripheral lung

Schematic wedge-shaped hemorrhagic infarct

Slide 37 · Pulmonary embolism: Clinical expression

Large emboli may cause sudden collapse and hemodynamic shock.

Symptomatic cases may present with dyspnea, pleuritic pain, and cough.

Hemoptysis and fever can accompany pulmonary infarction.

Slide 38 · Factor V Leiden: Inherited thrombophilia

Factor V Leiden is a factor V variant resistant to inactivation by activated protein C.

This weakens an important physiological anticoagulant pathway.

Higher thrombotic risk when this mutation and certain contraceptive exposures coexist.

Factor V Leiden mutation

Reduced protein C inactivation

Persistent procoagulant activity

Inherited mechanism

Slide 39 · Combined inherited and acquired risk

Inherited factor

Factor V Leiden

Protein C resistance

Acquired factor

Hormonal exposure

Coagulation-factor shift

An inherited propensity to thrombosis may be clinically silent until another prothrombotic exposure occurs.

Oral contraception adds an acquired component to an existing susceptibility.

The relevant question is cumulative risk, not whether one exposure is the sole cause.

Slide 40 · Third-generation formulations: Careful interpretation

A potentially greater thrombosis risk with some third-generation synthetic-progestin OCs.

The text emphasizes especially susceptible women carrying factor V Leiden.

The observation should not be generalized to all progestins or progestin-only contraception.

Slide 41 · Risk comparison: Contraception versus pregnancy

OC-associated versus pregnancy-associated VTE

2–6× lower

VTE risk associated with contraceptive use is two to six times lower than that associated with pregnancy.

This is a contextual comparison of thromboembolic hazards.

Risk assessment should consider both the exposure and the alternative state of pregnancy.

Slide 42 · Relative risk is not absolute incidence

Relative measure

Ratio of event probabilities

Robbins gives 2–4×

Absolute measure

Events per population/time

Not supplied in passage

A 2–4-fold relative risk does not specify how many patients have an event.

Absolute risk depends on the baseline population and additional risk factors.

Avoid drawing incidence curves or counts when no denominators are supplied.

Slide 43 · How to read a thrombotic risk statement

Identify the outcome: DVT, PE, or combined VTE.

Identify comparator, duration of exposure, and hormonal formulation.

Account for smoking, inherited susceptibility, pregnancy, and other co-exposures where data allow.

Slide 44 · Arterial and venous events are distinct

Venous

DVT / pulmonary embolism

Hypercoagulability prominent

Arterial

Atherosclerosis / MI

Different causal context

Venous thrombosis is strongly linked to acquired hypercoagulability.

Coronary artery disease and myocardial infarction involve different vascular pathophysiology.

The strength and certainty of the associations are not interchangeable.

Slide 45 · Coronary disease: Uncertainty in the source

Considerable uncertainty regarding atherosclerosis and myocardial infarction among OC users.

Avoid presenting a uniform dose-independent increase or decrease in coronary risk.

Age and smoking status are explicitly relevant modifiers.

Slide 46 · Younger OC users: Coronary risk statement

The textbook finds no apparent increase in coronary artery disease in females younger than 30 years.

This is an age-group summary, not a guarantee of individual safety.

VTE and hepatic adenoma risks are separate endpoints.

Slide 47 · Older nonsmokers: Coronary risk statement

No apparent increased coronary disease risk in older women who do not smoke.

The group distinction reflects effect modification by other vascular risks.

Do not treat the statement as evidence about all formulations and all vascular outcomes.

Slide 48 · Women older than 35 who smoke

Smokers older than 35 years

≈2× coronary risk

That coronary risk approximately doubles among female OC users older than 35 years who smoke.

Both age and smoking are relevant to interpretation.

This passage is an association and does not quantify absolute myocardial infarction incidence.

Slide 49 · Why smoking status changes interpretation

A comparison that ignores smoking may combine biologically different vascular-risk groups.

A treatment effect estimated in nonsmokers should not be assumed to apply in smokers.

This is an example of risk-stratified interpretation rather than a universal contraceptive contraindication rule.

Slide 50 · Avoid conflating VTE and myocardial infarction

VTE

2–4× relative increase: Reported in the source

Coronary disease

Uncertain overall; Smoking/age interaction

Risk explanation

Different vascular endpoints

The source offers a stronger and more explicit quantitative VTE association.

The coronary disease assessment is qualified by uncertainty and subgroup differences.

Risk communication should retain both the outcome and its evidentiary confidence.

Slide 51 · Hepatocellular adenoma: An exposure-associated tumor

Hepatocellular adenoma is a benign hepatocytic neoplasm.

A strong association with oral contraceptives, especially prolonged exposure.

The liver chapter also describes associations with anabolic steroids and metabolic factors.

Slide 52 · Clinical context of the association

Prolonged OC exposure, particularly in older female users, in its adverse-effect section.

The liver chapter describes many tumors in young women and the roles of obesity and metabolic syndrome.

These statements describe overlapping but not identical risk strata.

Slide 53 · Hepatocellular adenoma: Gross morphology

A discrete hepatic mass is characteristic.

Hemorrhage may occur within or around the lesion.

Tumors can present incidentally or with pain or hemorrhagic necrosis.

Schematic hepatic mass — not a specimen

Slide 54 · Hepatocellular adenoma: Basic histology

Neoplastic hepatocytes are arranged in plates approximately one to two cells thick.

Large arteries can be present within scant fibrous stroma.

Normal portal tracts and interlobular bile ducts are absent within the lesion.

Schematic hepatocyte plates; No portal tract

Slide 55 · Why absent portal tracts matter

Normal liver architecture

Portal tracts present

Interlobular bile ducts present

Hepatocellular adenoma

Absent normal portal tracts

No interlobular ducts

Portal tracts normally contain a portal venous branch, hepatic arterial branch, and bile duct.

Their absence in hepatocellular adenoma is a useful architectural discriminator.

It must be assessed in tissue context rather than inferred from a single missing structure.

Slide 56 · Adenoma is heterogeneous at the molecular level

HNF1A-inactivated

Fat-rich; LFABP loss

Inflammatory

JAK–STAT; CRP/SAA expression

β-catenin–activated

Wnt activation; Subtype-specific malignancy risk

Sonic hedgehog

GLI1 fusion; Hemorrhage propensity

Slide 57 · HNF1A-inactivated adenoma

HNF1A loss-of-function can lead to conspicuous lesional steatosis.

Loss of liver fatty acid–binding protein expression is a characteristic immunophenotypic feature.

Comparatively little risk of malignant transformation in this subtype.

Slide 58 · Inflammatory hepatocellular adenoma

Activating gp130/IL-6–pathway alterations stimulate JAK–STAT signaling.

Inflammatory adenomas may show sinusoidal dilation and mimic focal nodular hyperplasia.

CRP and serum amyloid A are upregulated in neoplastic hepatocytes.

Gp130 / IL-6 signaling

Constitutive JAK–STAT activity

CRP / SAA upregulation

Inflammatory subtype

Slide 59 · β-catenin–activated adenoma

CTNNB1 or related Wnt-pathway alterations activate β-catenin signaling.

High-level activation, notably some CTNNB1 exon 3 alterations, is linked to malignant transformation risk.

Nuclear β-catenin immunoreactivity may support pathway activation.

Wnt-pathway alteration

β-catenin activation

Higher-risk neoplastic phenotype

Wnt-related subtype

Slide 60 · Sonic hedgehog adenoma

The source describes GLI1 fusion-driven activation of hedgehog signaling.

This subtype has an important propensity to hemorrhage.

A benign label does not exclude potentially life-threatening bleeding.

GLI1 fusion

Hedgehog-pathway activation

Hemorrhage propensity

Molecular-to-clinical link

Slide 61 · Hemorrhage and rupture

Hemorrhagic necrosis may produce abdominal pain.

Rupture of a hepatocellular adenoma can cause massive intra-abdominal hemorrhage.

This is a clinically serious complication of a histologically benign neoplasm.

Slide 62 · Malignant transformation is subtype-dependent

Lower-risk pattern

HNF1A-inactivated subtype

Minimal malignant transformation risk

Higher-risk pattern

Certain β-catenin–activated lesions

Transformation concern

β-catenin pathway activation is a key determinant of increased malignant potential.

Risk is not identical across all hepatocellular adenomas.

Morphology, molecular classification, and clinical context jointly inform assessment.

Slide 63 · Textbook management implications of adenoma

Robbins recommends resection for male patients, β-catenin–activated tumors, and lesions measuring at least 5 cm.

Smaller lesions without β-catenin activation may be followed, with cessation of relevant hormone or steroid exposure.

These are textbook statements, not independently validated contemporary management guidelines.

Slide 64 · Hepatocellular adenoma versus FNH

Hepatocellular adenoma

Neoplastic hepatocytes

Portal tracts absent

Hormone association

Focal nodular hyperplasia

Non-neoplastic response

Central scar / ductular reaction

Altered perfusion

Focal nodular hyperplasia is a non-neoplastic hyperplastic lesion related to altered vascular flow.

FNH typically has a central scar and ductular reaction; Adenoma lacks normal portal tracts and ducts.

Inflammatory adenoma may mimic FNH, so pattern recognition alone has limits.

Slide 65 · Other hepatic adverse reaction: Cholestasis

Cholestasis

Drug-associated bile-flow disturbance

Non-neoplastic injury

Hepatocellular adenoma

Benign hepatocyte neoplasm

Mass lesion / hemorrhage

The general adverse-drug-reaction table lists estrogens and contraceptive agents among causes of cholestasis.

This drug-associated liver injury should not be confused with hepatocellular adenoma.

Cholestasis and neoplasia represent different pathologic response types.

Slide 66 · Balance favorable and unfavorable outcomes

Favorable

Endometrial and ovarian cancer associations

Potentially harmful

VTE; Hepatic adenoma; Possible cervical risk

Dependent on subgroup

Coronary outcomes by age/smoking

Endometrial and ovarian cancer protection coexist with potential venous thrombotic harm.

HPV-associated cervical risk and liver adenoma are distinct concerns requiring their own contexts.

Cancer, vascular, and liver endpoints should not be compressed into a single “safe/unsafe” category.

Slide 67 · Case: Thrombosis with inherited susceptibility

A person taking combined oral contraception develops a deep vein thrombosis and is found to carry factor V Leiden.

Interpretation question

Which elements are inherited and which are acquired?

Answer: Protein C–resistant factor V is inherited; Hormone-associated coagulation shift is acquired.

Slide 68 · Case: A smoking-related coronary concern

A 38-year-old current smoker asks whether OC-associated vascular risk is identical to that in a 25-year-old nonsmoker.

Interpretation question

How does the Robbins passage stratify coronary risk?

Answer: Its higher coronary-risk statement applies specifically to smokers older than 35, not all users.

Slide 69 · Case: Benign mass with serious consequences

A long-term OC user has a discrete hepatocytic liver mass with hemorrhage and no portal tracts.

Interpretation question

Which lesion is most consistent with the described architecture?

Answer: Hepatocellular adenoma; Rupture and molecular subtype are important next considerations.

Slide 70 · Case: A cervical-cancer association

An epidemiologic study reports cervical carcinoma among HPV-infected OC users.

Interpretation question

Can the OC exposure replace high-risk HPV as the principal etiologic explanation?

Answer: No. High-risk HPV drives cervical carcinogenesis; OCs are described as a possible risk modifier.

Slide 71 · A structured clinicopathologic interpretation

First specify formulation, dose, duration, and route when known.

Next identify the exact pathology endpoint and major host cofactors.

Then separate a mechanistic explanation from an observational association and state uncertainty.

Characterize exposure

Identify organ endpoint + cofactors

Interpret strength of evidence

Reasoning workflow

Slide 72 · Core pathology conclusions

Cancer associations are organ-specific: Protective at endometrium/ovary, possible conditional cervical risk, source-qualified breast statement.

Acquired hypercoagulability links hormonal exposure with DVT and pulmonary embolism.

Hepatocellular adenoma is a hormone-associated benign tumor with hemorrhagic and subtype-dependent malignant risks.

Slide 73 · Primary textbook references

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026). Chapter 9, “Oral Contraceptives,” pp. 384–385.

Chapter 4: thrombosis, hypercoagulability, and factor V Leiden; Chapter 15: pulmonary embolism.

Chapter 18, pp. 788–790: hepatocellular adenoma; Chapter 22, pp. 905–909: HPV-mediated cervical carcinogenesis.